肟醚噻二唑硫醚化合物的合成及其抗肿瘤活性

将2-巯基-5-取代基-1,3,4-噻二唑经与β-氯苯丙酮取代、盐酸羟胺肟化和氯甲基噁二唑醚化,合成了6种3-(5-取代基-1,3,4-噻二唑-2-硫代基)-1-苯基丙酮-O-(5-苯基-1,3,4-噁二唑-2-甲基)肟醚化合物(4a~4f),用1H NMR、IR、MS和元素分析表征了其结构。 用MTT法测试了6种目标化合物对人黑色素瘤细胞株B16、人白血病细胞株HL60和人肝癌细胞株SMMC-7721的体外细胞毒活性。 测试结果表明,部分化合物对3种癌细胞具有潜在的体外生长抑制活性。     

新型含哌嗪-磺酰胺的2(5H)-呋喃酮类化合物的合成及其抗癌活性

以糠醛为原料,经氧化、醚化和重结晶制得5-甲氧基-3,4-二溴-2(5H)-呋喃酮（4）; 4与哌嗪经Michael加成消除反应制得5-甲氧基-4-哌嗪基-3-溴-2(5H)-呋喃酮（5）; 5与取代磺酰氯经磺酰化反应合成了7 个新型的含哌嗪-磺酰胺的2(5H)-呋喃酮类化合物(7a~7g),其结构经¹H NMR, ¹³C NMR, IR和HR-MS表征。初步的生物活性研究(MTT法)表明,7a~7g均能显著抑制人宫颈癌Hela细胞的增殖,其中5-甲氧基-4-(对乙酰氨基苯磺酰基-哌嗪基)-3-溴-2(5H)-呋喃酮（7f）的抑制活性最佳,其IC₅₀为0.03 μM(24 h)。     

新型芳姜黄酮拼合吡咯螺环氧化吲哚类化合物的合成及其抗肿瘤活性

以取代靛红和肌氨酸为原料制得1,3-偶极子,再与(E)-芳姜烯酮类化合物在乙腈中经3+2环加成反应合成了10个新型的芳姜黄酮拼合吡咯螺环氧化吲哚类化合物(3a~3j)产率70%~91%, d/r值15 :1~>20:1,其结构经¹H NMR, ¹³C NMR和HR-MS（ESI-TOF）表征。采用MTT法研究了3a~3j对人肺癌细胞(A549)和人白血病细胞(K562)的体外抗肿瘤活性。结果表明：3f对K562抑制活性较好（IC₅₀=31.1 μmol·L^-1）, 3b对A549抑制活性较好（IC₅₀=54.1 μmol·L^-1）。     

Syntheses Based on 3,4α-Epoxy-1,5,7α,6β(H)-guai-10(14),11(13)-dien-6,12-olide

The sesquiterpene γ-lactone estafiatin 1, the molecule of which has a structure of 3,4α-epoxy-1,5,7α,6β(H)-guai-10(14),11(13)-dien-6,12-olide, is characteristic of plants of the genera Achillea L. and Artemisia L. of the Asteraceae family. This article presents the results of chemical modification for three reaction centers of the estafiatin molecule 1: epoxy cycle, exomethylene group conjugated with γ-lactone carbonyl, and exomethylene group in position C10=C14; and at the same time 33 new derivatives were synthesized, the structures of which were established based on physicochemical constants, spectral data (IR-, PMR-, ¹³C-NMR), and X-ray diffraction analysis. The stereo- and regiospecificity, as well as the chemoselectivity of the reaction based on estafiatin molecule 1, are discussed. The reactivity of the substrate is significantly influenced by the stereochemistry of its molecule, the nature of the reagent, and the reaction medium. Based on the results of in silico screening, derivatives of estafiatin with high binding energies for both DNA-topoisomerase I and DNA-topoisomerase II were identified. The values of the inhibitory dose of IC₅₀ for estafiatin 1 and its derivatives were determined on cell lines of eight types of tumors. in vivo experiments of the samples made it possible to establish that estafiatin 1 and its derivatives have pronounced antitumor activity against Pliss lymphosarcoma, Walker’s carcinosarcoma, sarcoma 45, sarcoma-180, alveolar liver cancer PC-1, leukemia P-388 and L-1210, and sarcoma-45 resistant to 5-fluorouracil.     

非铂类金属抗肿瘤药物的研究进展

自从顺铂被发现具有抗肿瘤活性以来,金属抗肿瘤药物得到了飞速的发展,一些非铂类金属的化合物也相继被发现具有一定的抗肿瘤活性。与铂类金属药物相比,非铂类金属抗肿瘤药物的发展相对缓慢,但也取得了一定的成果。本文主要就一些已经进入临床试验阶段的非铂类抗肿瘤药物的研究进展作一简述。     

Antioxidant and Antitumor Activities of Newly Synthesized Hesperetin Derivatives

Hesperetin is a class of natural products with a wide range of sources and remarkable biological activities. In this study, we described the synthesis of a series of novel hesperetin derivatives and evaluated the in vitro antioxidant and antitumor activity of these compounds. Eleven novel compounds were synthesized in moderate yields. The compounds synthesized in this work exhibited antioxidant activities against DPPH and ABTS free radicals in a dose-dependent manner. Among them, compound 3f had the best antioxidant activity, with IC₅₀ of 1.2 μM and 24 μM for DPPH and ABTS, respectively. The antitumor activity of the compounds against human cancer cell lines, such as breast MCF-7, liver HepG2, and cervical Hela, was determined by a standard 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Three compounds had moderate IC₅₀ values. Interestingly, compound 3f had better biological activity than hesperetin, which matches the prediction by Maestro from Schrödinger. Therefore, the new hesperidin derivative is a promising drug for the treatment of cancer due to its effective antitumor activity. The results also suggested that the antitumor activities of hesperetin derivatives may be related to their antioxidant activities.     

2-取代硫醚-5-(3,4,5-三甲氧基苯基)-1,3,4-噻二唑类化合物的合成、结构与体外抗癌活性

以天然产物没食子酸为原料经醚化、酯化、酰肼化、成盐、闭环、硫醚化六步反应合成了6个2-取代硫醚-5-(3,4,5-三甲氧基苯基)-1,3,4-噻二唑类衍生物, 釆用铟催化下水相合成目标化合物8, 具有反应条件温和, 合成收率高的特点; 用IR, ¹H NMR, ¹³C NMR和元素分析对各化合物进行了表征及结构确证, 并用X射线单晶衍射法测定了化合物8a [2-(2-氯-5-吡啶甲基)硫醚-5-(3,4,5-三甲氧基苯基)-1,3,4-噻二唑]的晶体结构, 采用MTT法进行了新化合物抑制PC3和BGC-823癌细胞体外试验, 结果表明在5μmol•L^－1浓度下化合物8e对PC3的抑制活性为55.71%. 化合物8b对BGC-823细胞抑制活性为66.21%.     

Ph~2C(OH)CH=CHSnAr~3的卤化物的合成、表征和性质

首次以非碳环醇(Z)-3-三芳基锡基-1,1-二苯基-2-丙烯基-1-醇[Ph~2C(OH)CH=CHSnAr~3]和卤素或拟卤素发生取代反应得到卤化物,并以此合成了氢氧化物、氧化物和配合物。通过元素分析、IR和^1HNMR等对上述17种新化合物的结构进行了表征,并提出了卤化物的性质。     

pH药物控释的氮掺杂碳点载运阿霉素用于光热与化疗的协同治疗

提出一种利用氮掺杂碳点(N-CDs)的光热性能与化疗药物阿霉素(Dox)相结合的联合治疗肿瘤模式。实验结果标明,所制备的N-CDs的分散液经光照后升温可达10℃,是性能优异的光热剂。同时,载运Dox后的N-CDs-Dox纳米复合物还具有pH触发的药物控释作用。因此,这种多功能的N-CDs-Dox纳米复合物能够实现光热和化疗的协同作用,有效杀伤肿瘤细胞。     

5-氟尿嘧啶卟啉锰/锌配合物的合成、光电性质及抗癌活性

合成了新型5-氟尿嘧啶修饰的自由卟啉5-(2-(5-氟尿嘧啶-3-基)乙氧基苯基)-10,15,20-三苯基卟啉(L)及其锰配合物(MnL)和锌配合物(ZnL)。通过紫外-可见光谱、红外光谱、核磁共振氢谱及高分辨质谱等手段进行了结构表征。研究了它们的荧光性质和电化学性质;应用标准磺酰罗丹明B法(SRB法)测试了目标化合物对人肺癌细胞株A549、人肝癌细胞株Bel-7402和人结肠癌细胞株HCT-8生长的抑制活性。结果表明:相同实验条件下,不同金属离子对配合物的荧光强度存在较大影响:锌配合物具有荧光猝灭的性质,而锰配合物未能观察到明显的荧光发射光谱;与自由卟啉和锌配合物相比,锰配合物除卟啉环发生氧化还原反应外,Mn~(2+)自身也发生了氧化还原反应;抗癌活性测试显示锰配合物较其他2种化合物有较好的抗癌活性。